Efficacy of PARPi monotherapy and the impact to subsequent platinum-based chemotherapy in BRCA1/2 -mutated ovarian cancer patients with secondary platinum-sensitive relapse
Yana Ma12*, Ning Li3*, Hualei Bu12*, Yongwen Huang4, Chengjuan Jin5, Hao Wen6, Shuai Feng7, Hui Zhang8, Beihua Kong12, Lingying Wu3#, Kun Song12#
* Contributed equally
1 Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, 250012, China
2 Division of Gynecology oncology, Qilu Hospital of Shandong University, Jinan, 250012, China
3 Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
4 Gynecologic Department, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China
5 Department of Obstetrics and Gynecology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 201620, China
6 Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, 201620, China.
7 Gynecological Oncology Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250012, China
8 Department of Gynecology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, China.